Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
复制标题
DOI：
10.1186/s12933-015-0206-3
复制
发表时间：
2015-04-22
影响因子：
9.3
通讯作者：
Prescott E
中科院分区：
文献类型：
--
作者：
Faber R;Zander M;Pena A;Michelsen MM;Mygind ND;Prescott E
Impaired coronary microcirculation is associated with a poor prognosis in patients with type 2 diabetes. In the absence of stenosis of major coronary arteries, coronary flow reserve (CFR) reflects coronary microcirculation. Studies have shown beneficial effects of glucagon-like peptide-1 (GLP-1) on the cardiovascular system. The aim of the study was to explore the short-term effect of GLP-1 treatment on coronary microcirculation estimated by CFR in patients with type 2 diabetes. Patients with type 2 diabetes and no history of coronary artery disease were treated with either the GLP-1 analogue liraglutide or received no treatment for 10 weeks, in a randomized, single-blinded, cross-over setup with a 2 weeks wash-out period. The effect of liraglutide on coronary microcirculation was evaluated using non-invasive trans-thoracic Doppler-flow echocardiography during dipyridamole induced stress. Peripheral microvascular endothelial function was assessed by Endo-PAT2000®. Interventions were compared by two-sample t-test after ensuring no carry over effect. A total of 24 patients were included. Twenty patients completed the study (15 male; mean age 57 ± 9; mean BMI 33.1 ± 4.4, mean baseline CFR 2.35 ± 0.45). There was a small increase in CFR following liraglutide treatment (change 0.18, CI95% [-0.01; 0.36], p = 0.06) but no difference in effect in comparison with no treatment (difference between treatment allocation 0.16, CI95% [-0.08; 0.40], p = 0.18). Liraglutide significantly reduced glycated haemoglobin (HbA1c) (-10.1 mmol/mol CI95% [-13.9; -6.4], p = 0.01), systolic blood pressure (-10 mmHg CI95% [-17; -3], p = 0.01) and weight (-1.9 kg CI95% [-3.6; -0.2], p = 0.03) compared to no treatment. There was no effect on peripheral microvascular endothelial function after either intervention. In this short-term treatment study, 10 weeks of liraglutide treatment had no significant effect on neither coronary nor peripheral microvascular function in patients with type 2 diabetes. Further long-term studies, preferably in patients with more impaired microvascular function and using a higher dosage of GLP-1 analogues, are needed to confirm these findings. ClinicalTrials.gov: NCT01931982. The online version of this article (doi:10.1186/s12933-015-0206-3) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
9.3
作者：
Kawata, Takayuki;Daimon, Masao;Daida, Hiroyuki
通讯作者：
Daida, Hiroyuki
影响因子：
5.7
作者：
Read, Philip A.;Khan, Fakhar Z.;Dutka, David P.
通讯作者：
Dutka, David P.
影响因子：
7.7
作者：
Noyan-Ashraf MH;Momen MA;Ban K;Sadi AM;Zhou YQ;Riazi AM;Baggio LL;Henkelman RM;Husain M;Drucker DJ
通讯作者：
Drucker DJ
DOI：
10.1016/s0735-1097(99)00342-3
发表时间：
1999-10-01
影响因子：
24
作者：
Caiati, C;Montaldo, C;Iliceto, S
通讯作者：
Iliceto, S
影响因子：
5.4
作者：
Ayaori M;Iwakami N;Uto-Kondo H;Sato H;Sasaki M;Komatsu T;Iizuka M;Takiguchi S;Yakushiji E;Nakaya K;Yogo M;Ogura M;Takase B;Murakami T;Ikewaki K
通讯作者：
Ikewaki K